142 related articles for article (PubMed ID: 36007313)
1. Glycyrrhetinic acid proliposomes mediated by mannosylated ligand: Preparation, physicochemical characterization, environmental stability and bioactivity evaluation.
Chen J; Lin Y; Wu M; Li C; Cen K; Liu F; Liao Y; Zhou X; Xu J; Cheng Y
Colloids Surf B Biointerfaces; 2022 Oct; 218():112781. PubMed ID: 36007313
[TBL] [Abstract][Full Text] [Related]
2. Drug-Free Liposomes Containing Mannosylated Ligand for Liver-Targeting: Synthetic Optimization, Liposomal Preparation, and Bioactivity Evaluation.
Chen J; Lin Y; Wu M; Li C; Zhang Y; Chen D; Cheng Y
J Biomed Nanotechnol; 2021 Dec; 17(12):2455-2465. PubMed ID: 34974868
[TBL] [Abstract][Full Text] [Related]
3. Glycyrrhetinic Acid Liposomes Containing Mannose-Diester Lauric Diacid-Cholesterol Conjugate Synthesized by Lipase-Catalytic Acylation for Liver-Specific Delivery.
Chen J; Chen Y; Cheng Y; Gao Y
Molecules; 2017 Sep; 22(10):. PubMed ID: 28946644
[TBL] [Abstract][Full Text] [Related]
4. Preparation, evaluation, and
Pan X; Liu S; Ju L; Xi J; He R; Zhao Y; Zhuang R; Huang J
Drug Dev Ind Pharm; 2020 Nov; 46(11):1889-1897. PubMed ID: 32975456
[TBL] [Abstract][Full Text] [Related]
5. Dual-Ligand-Functionalized Liposomes Based on Glycyrrhetinic Acid and cRGD for Hepatocellular Carcinoma Targeting and Therapy.
Qiu M; Wang J; Bai J; Li X; Tian C; Liu Z; Zheng C; Clark AR; Cheng X; Liao X; Wu S; Lee RJ; Zhou X
Mol Pharm; 2023 Apr; 20(4):1951-1963. PubMed ID: 36952242
[TBL] [Abstract][Full Text] [Related]
6. Development of Glycyrrhetinic Acid and Folate Modified Cantharidin Loaded Solid Lipid Nanoparticles for Targeting Hepatocellular Carcinoma.
Xu Y; Wang M; Ning S; Yang Z; Zhou L; Xia X
Molecules; 2022 Oct; 27(20):. PubMed ID: 36296377
[TBL] [Abstract][Full Text] [Related]
7. Development of Salvianolic acid B-Tanshinone II A-Glycyrrhetinic acid compound liposomes: formulation optimization and its effects on proliferation of hepatic stellate cells.
Lin J; Wang X; Wu Q; Dai J; Guan H; Cao W; He L; Wang Y
Int J Pharm; 2014 Feb; 462(1-2):11-8. PubMed ID: 24374609
[TBL] [Abstract][Full Text] [Related]
8. [Preparation and in vivo study of liposomes mediated by glycyrrhetinic acid derivative ligand 18-GA-Gly].
Jin S; Wang XL; Li G
Zhongguo Zhong Yao Za Zhi; 2017 Nov; 42(21):4120-4126. PubMed ID: 29271149
[TBL] [Abstract][Full Text] [Related]
9. Preparation and evaluation of cyclosporin A-containing proliposomes: a comparison of the supercritical antisolvent process with the conventional film method.
Karn PR; Jin SE; Lee BJ; Sun BK; Kim MS; Sung JH; Hwang SJ
Int J Nanomedicine; 2014; 9():5079-91. PubMed ID: 25395846
[TBL] [Abstract][Full Text] [Related]
10. Daptomycin Proliposomes for Oral Delivery: Formulation, Characterization, and In Vivo Pharmacokinetics.
Arregui JR; Kovvasu SP; Betageri GV
AAPS PharmSciTech; 2018 May; 19(4):1802-1809. PubMed ID: 29616488
[TBL] [Abstract][Full Text] [Related]
11. Preparation and characterization of galactose-modified liposomes by a nonaqueous enzymatic reaction.
Guo BH; Cheng Y; Lin LP; Lin DH; Wu W
J Liposome Res; 2011 Sep; 21(3):255-60. PubMed ID: 21545336
[TBL] [Abstract][Full Text] [Related]
12. Construction of redox-sensitive liposomes modified by glycyrrhetinic acid and evaluation of anti-hepatocellular carcinoma activity.
Hu J; Zheng Y; Wen Z; Fu H; Yang X; Ye X; Zhu S; Kang L; Li X; Yang X; Hu Y
Chem Phys Lipids; 2023 May; 252():105292. PubMed ID: 36931583
[TBL] [Abstract][Full Text] [Related]
13. Proliposomes for oral delivery of dehydrosilymarin: preparation and evaluation in vitro and in vivo.
Chu C; Tong SS; Xu Y; Wang L; Fu M; Ge YR; Yu JN; Xu XM
Acta Pharmacol Sin; 2011 Jul; 32(7):973-80. PubMed ID: 21666703
[TBL] [Abstract][Full Text] [Related]
14. Glycyrrhetinic Acid and TAT Peptide Modified Dual-functional Liposomes for Treatment of Hepatocellular Cancer.
Huang S; Ren D; Wu X; Li M; Yu X; Nie X; Wang Y; Wang Y
Curr Top Med Chem; 2020; 20(27):2493-2505. PubMed ID: 32703132
[TBL] [Abstract][Full Text] [Related]
15. Design of novel proliposome formulation for antioxidant peptide, glutathione with enhanced oral bioavailability and stability.
Byeon JC; Lee SE; Kim TH; Ahn JB; Kim DH; Choi JS; Park JS
Drug Deliv; 2019 Dec; 26(1):216-225. PubMed ID: 30843439
[TBL] [Abstract][Full Text] [Related]
16. Spray-Dried Proliposome Microparticles for High-Performance Aerosol Delivery Using a Monodose Powder Inhaler.
Omer HK; Hussein NR; Ferraz A; Najlah M; Ahmed W; Taylor KMG; Elhissi AMA
AAPS PharmSciTech; 2018 Jul; 19(5):2434-2448. PubMed ID: 29872976
[TBL] [Abstract][Full Text] [Related]
17. A novel glycyrrhetinic acid-modified oxaliplatin liposome for liver-targeting and in vitro/vivo evaluation.
Chen J; Jiang H; Wu Y; Li Y; Gao Y
Drug Des Devel Ther; 2015; 9():2265-75. PubMed ID: 25945038
[TBL] [Abstract][Full Text] [Related]
18. Development and in vivo evaluation of functionalized ritonavir proliposomes for lymphatic targeting.
Ahammed V; Narayan R; Paul J; Nayak Y; Roy B; Shavi GV; Nayak UY
Life Sci; 2017 Aug; 183():11-20. PubMed ID: 28647214
[TBL] [Abstract][Full Text] [Related]
19. Hepatocellular Carcinoma Targeting and Pharmacodynamics of Paclitaxel Nanoliposomes Modified by Glycyrrhetinic Acid and Ferric Tetroxide.
Zhao L; Liang L; Guo M; Li M; Yu X; Wang Y; Wang Y
Curr Top Med Chem; 2021 Oct; 21(14):1268-1284. PubMed ID: 34620053
[TBL] [Abstract][Full Text] [Related]
20. 3D-printed microfluidic chip for the preparation of glycyrrhetinic acid-loaded ethanolic liposomes.
Tiboni M; Benedetti S; Skouras A; Curzi G; Perinelli DR; Palmieri GF; Casettari L
Int J Pharm; 2020 Jun; 584():119436. PubMed ID: 32445905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
